Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Class C cephalosporinases, also known as AmpC β-lactamases, are enzymes produced by various Gram-negative bacteria. Their primary function is to hydrolyze and inactivate a broad range of β-lactam antibiotics, particularly cephalosporins. These enzymes play a significant role in antibiotic resistance. They are typically encoded by chromosomal genes but can also be found on plasmids. Expression is often inducible. Class C cephalosporinases are widespread among Gram-negative bacteria, including Enterobacter, Citrobacter, Serratia, Proteus, Pseudomonas aeruginosa, and some strains of E. coli, making them major contributors to hospital-acquired infections with multidrug-resistant phenotypes. Classic inhibitors such as clavulanic acid do not inhibit class C enzymes effectively; however, newer agents like avibactam show inhibitory activity.
Antibiotic inactivation
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Class C Cephalosporinase (AmpC).